BB Heathcare Trust PLC

Name
BB Heathcare Trust PLC
Manager
Bellevue Asset Management AG
Type
Closed Ended Investment Company
ISIN
GB00BZCNLL95
Sector
Sector Specialist: Biotechnology & Healthcare
Launched
02/12/2016
OCF
1.36 %
Yield
0 %
Benchmark
MSCI World/Health Care GR USD
Fund Size
£ 478.33 million
NAV
129
Gearing
112
Discount Premium
2
The company aims to provide capital growth and income over the long term, through investment in listed or quoted global healthcare companies. The specific return objectives are to beat the total return of the MSCI World Healthcare Index (in sterling) on a rolling 3-year period and to seek to generate a double-digit total shareholder return p.a. over a rolling 3-year period. It may also invest in ADRs, or convertible instruments issued by such companies and may invest in, or underwrite, future equity issues by such companies. The company may utilize contracts for differences for investment purposes in certain jurisdictions where taxation or other issues in those jurisdictions may render direct investment in listed or quoted equities less effective.
Holding %
Align Technology Inc 15.90 %
Illumina Inc 14.52 %
Teladoc Health Inc 13.85 %
Anthem Inc 12.30 %
Celgene Corp 10.70 %
Lonza Group Ltd 7.59 %
Bristol-Myers Squibb Company 7.35 %
Intuitive Surgical Inc 6.49 %
Esperion Therapeutics Inc 5.80 %
Ionis Pharmaceuticals Inc 5.51 %
Region %
United States 92.41 %
Europe - ex Euro 7.59 %
Sector %
Healthcare 86.15 %
Technology 13.85 %
Name
Bellevue Asset Management AG
Address
8700, Küsnacht, Switzerland
Legal Structure
Closed Ended Investment Company

Managers

Brett Darke
Joined 09/01/2017
Daniel Koller
Joined 12/02/2016
Paul Major
Joined 12/02/2016

Paul has 18 years of experience in the healthcare sector on the sell-side and was top-rated by a number of institutional investment clients. He was one of the first research partners at Redburn, Europe’s leading independent research firm. His work there included bespoke projects on healthcare portfolio construction for several institutions. Paul was previously an analyst and corporate financier at UBS Warburg and studied biochemistry.

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.